Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Fujifilm delivered strong FY2025 results, driven by progress on VISION2030 and a diversified business mix. Read why FUJIY ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

The global Retinal Vein Occlusion (RVO) treatment market was valued at approximately USD 2.65 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6.92% over the ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Review Regeneron Pharmaceuticals Inc (REGN:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and ...

Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma ...

Key factors fueling this trend include increased awareness, improved healthcare infrastructure, and enhanced diagnostic and treatment accessibility. With the prevalence of high myopia projected to ...